Compare Synchrony Financial (SYF) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs TransMedics Group Inc — how do they compare? Synchrony Financial trades at $79.4 (market cap $25.53B), while TransMedics Group Inc trades at $86.89 (market cap $3.10B). The key difference: Synchrony Financial is far larger — about 8.2× TransMedics Group Inc's market cap, and Synchrony Financial pays a 1.73% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SYF | TMDX | |
|---|---|---|
Market Cap | $25.53B | $3.10B |
Sector | Financials | Technology |
52-Week High | $88.47 | $150.42 |
52-Week Low | $63.78 | $61.99 |
Dividend Yield | 1.73% | — |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $78.78, up 0.75% today, with strong technical momentum as the stock tests resistance near $79. Recent earnings beats, including Q2 2026 EPS of $2.59 versus $2.14 expected, highlight robust fundamentals. The company maintains a net income margin of 23.4% and a low P/E of 8.05, signaling potential undervaluation. A new partnership with Stripe for CareCredit expansion and a $0.34 dividend reinforce positive business developments.
SYF presents a compelling investment case with analyst consensus bullish—62.5% buy ratings and an $86.33 price target imply ~10% upside. Risks include rising interest expenses of $4.14B and a projected negative net cash flow in 2026. Aggressive share buybacks and stable credit trends support upside, but macroeconomic pressures on consumer spending warrant monitoring.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
